Osteonecrosis of the jaw after oral bisphosphonate for osteoporosis.
Bisphosphonates are a common treatment for osteoporosis. Osteonecrosis of the jaw has been associated with the use of bisphosphonates, usually when they have been used parenterally to treat malignancies. Cases associated with oral bisphosphonate as a treatment for osteoporosis are less frequent. We describe two patients exhibiting the clinical manifestations of bisphosphonate-associated osteonecrosis of the jaw. A brief review of the literature on the incidence, possible risk factors, and practice guidelines is also presented.
Tong
C K
CK
Department of Orthopaedics and Traumatology, Caritas Medical Centre, Shamshuipo, Kowloon, Hong Kong.
Ho
S T
ST
Wong
S L
SL
D000284:Administration, Oral; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015994:Incidence; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology; D010024:Osteoporosis / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D012307:Risk Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates